Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$38000.0.

  • Cartesian Therapeutics' Cash from Financing Activities fell 10003.05% to -$38000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.2 million, marking a year-over-year decrease of 10397.3%. This contributed to the annual value of $168.4 million for FY2024, which is 138130.85% up from last year.
  • According to the latest figures from Q3 2025, Cartesian Therapeutics' Cash from Financing Activities is -$38000.0, which was down 10003.05% from $60000.0 recorded in Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' Cash from Financing Activities peaked at $124.5 million during Q3 2024, and registered a low of -$24.8 million during Q3 2023.
  • Moreover, its 5-year median value for Cash from Financing Activities was $1.1 million (2021), whereas its average is $13.3 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Cash from Financing Activities tumbled by 415049.02% in 2023 and then soared by 2877986.58% in 2024.
  • Cartesian Therapeutics' Cash from Financing Activities (Quarter) stood at $21.2 million in 2021, then plummeted by 97.11% to $612000.0 in 2022, then skyrocketed by 2200.82% to $14.1 million in 2023, then plummeted by 94.44% to $783000.0 in 2024, then crashed by 104.85% to -$38000.0 in 2025.
  • Its last three reported values are -$38000.0 in Q3 2025, $60000.0 for Q2 2025, and -$8.0 million during Q1 2025.